STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial

·STAT News··

Drugs called orexin agonists have been hailed for their ability to treat rare sleep disorders, but with new data, Alkermes is showing for the first time that the new class of therapies may benefit people with ADHD. In a randomized Phase 1 study, the company’s new drug, called ALKS 7290, was well tolerated and showed a signal of efficacy, Alkermes said Monday. Participants in the study started with a median score of 39 on a diagnostic known as the Adult ADHD Investigator Symptom Rating Scale, ind...

Read full article →

Related Articles

Does Employment Slow Cognitive Decline? Evidence from Labor Market Shocks
littlexsparkee · Hacker News · 6mo ago
Group averages obscure how an individual's brain controls behavior: study
hhs · Hacker News · 6mo ago
Underwater robot tracks sperm whale conversations in real time
thedebuglife · Hacker News · 6mo ago
Researchers print structural colour with an inkjet printer
zeristor · Hacker News · 6mo ago
Aging may be a program, not a breakdown
elo2000 · Hacker News · 1mo ago